Clinical Trial Update: Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. [Phase 3]

View source ↗

Summary

Phase 3 trial update on anti-Hepatitis B antibodies in children aged 9–10 following birth Hep B vaccine and a hexavalent DTaP-IPV-Hep B-PRP-T vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• DTaP-IPV-Hep B-PRP-T hexavalent vaccine
• Hep B antibodies

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED